STRIDE: a randomized trial of a lifestyle intervention to promote weight loss among individuals taking antipsychotic medications

BMC Psychiatry

Carla A Green¹  Nancy A Perrin¹  Scott Stumbo¹  Michael C Leo¹  Bobbi Jo H Yarborough¹ 

[1] Kaiser Permanente Center for Health Research, 3800 N. Interstate Avenue, Portland, OR 97227, USA

关键词: Lipids;    Blood pressure;    Diabetes risk;    Physical activity;    Weight loss;    Lifestyle change;    Obesity;    Serious mental illness;    Antipsychotic medications;   

Others  :  1123955
DOI  :  10.1186/1471-244X-13-238

 received in 2013-09-11, accepted in 2013-09-24,  发布年份 2013

【 摘 要 】

Background

Individuals diagnosed with serious mental illnesses are at increased risk of obesity- and cardiovascular-related morbidity and early mortality. Lifestyle interventions aimed at weight loss, even those adapted to suit the needs of this particular subgroup, have rarely produced clinically meaningful reductions in weight.

Methods/design

The STRIDE study is a multi-site, parallel, two-arm randomized controlled translational trial. Participants were recruited from community mental health clinics and an integrated not-for-profit health system. Participants were randomized either to usual care or to a 12-month intervention that consisted of: 1) weekly group participation for six months covering topics on nutrition, physical activity and lifestyle changes; 2) monthly group participation for an additional six month maintenance period; and 3) individual monthly contacts from intervention group facilitators during the second six month phase. All participants are assessed at baseline, 6, 12, and 24 months post-enrollment. Process and implementation evaluations are included and the study design includes a cost-utility analysis. Participants include 200 individuals with serious mental illness with an average age of 47.1 years, a mean body-mass index of 38.3 kg/m² and taking an average of 3.2 psychiatric medications at baseline. Baseline physiological measures included mean blood pressure (SBP/DBP) measurements of 119.2 (SD = 14.7)/79.4 (SD = 10.1); 35% reported a hypertension diagnosis and 11% took antihypertensive medications. Average lipid levels (mg/dL) were: a) triglycerides 188.0 (SD = 138.6), ranged from 43 to 1145; b) LDL 101.4 (SD = 32.9) and ranged from 17 to 185; c) HDL 45.8 (SD = 12.7) and ranged from 22 to 89; and d) total cholesterol 181.6 (SD = 39.7) and ranged from 50 to 324. Average fasting glucose levels were 108.9 (SD = 32.5) and ranged from 24 to 289. Average fasting insulin levels were 13.0 (SD=11.9) and ranged from 2 to 99.

Discussion

The STRIDE study is based on a modified version of the PREMIER comprehensive lifestyle intervention, DASH diet arm. STRIDE has successfully enrolled 200 individuals with serious mental illness in community-based settings. Baseline characteristics present a population at high risk for obesity-related negative health outcomes and demonstrate the need for evidence-based interventions to reduce these risks.

Trial registration

Clinical Trials.gov NCT00790517

【 授权许可】

   
2013 Yarborough et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, et al.: Obesity among those with mental disorders: a national institute of mental health meeting report. Am J Prev Med 2009, 36(4):341-350.
• [2]Newcomer JW: Metabolic syndrome and mental illness. Am J Manag Care 2007, 13(7 Suppl):S170-S177.
• [3]McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al.: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80(1):19-32.
• [4]Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G: Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004, 49(11):753-760.
• [5]Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL: Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996, 37(1):68-73.
• [6]Kohen D: Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry Suppl 2004, 47:S64-S66.
• [7]Kilbourne AM, Ignacio RV, Kim HM, Blow FC: Are VA patients with serious mental illness dying younger? Psychiatr Serv 2009, 60(5):589.
• [8]Lawrence D, Hancock KJ, Kisely S: The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ 2013, 346:f2539.
• [9]Saha S, Chant D, McGrath J: A systematic review of mortality in schizophrenia: Is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007, 64(10):1123-1131.
• [10]Colton CW, Manderscheid RW: Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3(2):A42.
• [11]Kilbourne AM, Morden NE, Austin K, Ilgen M, McCarthy JF, Dalack G, et al.: Excess heart-disease-related mortality in a national study of patients with mental disorders: Identifying modifiable risk factors. Gen Hosp Psychiatry 2009, 31(6):555-563.
• [12]Osborn DP, Baio G, Walters K, Petersen I, Limburg H, Raine R, et al.: Inequalities in the provision of cardiovascular screening to people with severe mental illnesses in primary care: cohort study in the United Kingdom THIN primary care database 2000–2007. Schizophr Res 2011, 129(2–3):104-110.
• [13]Kilbourne AM, McCarthy JF, Post EP, Welsh D, Pincus HA, Bauer MS, et al.: Access to and satisfaction with care comparing patients with and without serious mental illness. Int J Psychiatry Med 2006, 36(4):383-399.
• [14]Casagrande SS, Anderson CA, Dalcin A, Appel LJ, Jerome GJ, Dickerson FB, et al.: Dietary intake of adults with serious mental illness. Psychiatr Rehabil J 2011, 35(2):137-140.
• [15]Compton MT, Daumit GL, Druss BG: Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006, 14(4):212-222.
• [16]Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, et al.: Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008, 105(1–3):175-187.
• [17]Chaggar PS, Shaw SM, Williams SG: Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol 2011, 51(5):631-638.
• [18]Haupt DW, Newcomer JW: Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001, 62(Suppl 27):15-26. Discussion 40–1
• [19]Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al.: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002, 59(4):337-345.
• [20]Newcomer JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007, 68(Suppl 1):20-27.
• [21]Newcomer JW: Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68(Suppl 4):8-13.
• [22]Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
• [23]American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes: consensus statement. Diabetes Care 2004, 27(2):596-601.
• [24]Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, et al.: A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013, 17:1594-1602.
• [25]Yarborough BJ, Janoff SL, Stevens VJ, Kohler D, Green CA: Delivering a lifestyle and weight loss intervention to individuals in real-world mental health settings: lessons and opportunities. Transl Behav Med 2011, 1(3):406-415.
• [26]Bartels S, Desilets R: Health Promotion Programs for People with Serious Mental Illness (Prepared by the Dartmouth Health Promotion Research Team). Washington, D.C.: SAMHSA-HRSA Center for Integrated Health Solutions; 2012.
• [27]Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al.: Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003, 289(16):2083-2093.
• [28]Funk KL, Elmer PJ, Stevens VJ, Harsha DW, Craddick SR, Lin PH, et al.: PREMIER–a trial of lifestyle interventions for blood pressure control: intervention design and rationale. Health Promot Pract 2006, 9(3):271-280.
• [29]McGuire HL, Svetkey LP, Harsha DW, Elmer PJ, Appel LJ, Ard JD: Comprehensive lifestyle modification and blood pressure control: a review of the PREMIER trial. J Clin Hypertens (Greenwich) 2004, 6(7):383-390.
• [30]Svetkey LP, Harsha DW, Vollmer WM, Stevens VJ, Obarzanek E, Elmer PJ, et al.: Premier: a clinical trial of comprehensive lifestyle modification for blood pressure control: rationale, design and baseline characteristics. Ann Epidemiol 2003, 13(6):462-471.
• [31]Ard JD, Grambow SC, Liu D, Slentz CA, Kraus WE, Svetkey LP: The effect of the PREMIER interventions on insulin sensitivity. Diabetes Care 2004, 27(2):340-347.
• [32]NHLBI Obesity Education Initiative Expert Panel: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report. Bethesda, MD: National Heart Lung and Blood Institute; 1998:1-228.
• [33]NHLBI Obesity Education Initiative Expert Panel: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The executive summary. Bethesda, MD: National Heart, Lung, Blood Institute; 1998:vii-xxvi.
• [34]Watson DL, Tharp RG: Self-directed behavior: Self-modification for personal adjustment. 8th edition. Belmont, CA: Wadsworth/Thomson Learning; 2002.
• [35]Prochaska JO, Velicer WF: The transtheoretical model of health behavior change. Am J Health Promot 1997, 12(1):38-48.
• [36]Burke BL, Arkowitz H, Dunn C, et al.: The efficacy of motivational interviewing and its adaptations: what we know so far. In Motivational Interviewing: Preparing People to Change Addictive Behavior. Edited by Miller WR, Rollnick S. New York, NY: The Guilford Press; 2002:217-250.
• [37]Rollnick S, Allison J, Ballasiotes S, Barth T, Butler CC, Rose GS, et al.: Variations on a theme: motivational interviewing and its adaptation. In Motivational Interviewing: Preparing People to Change Addictive Behavior. 2nd edition. Edited by Miller WR, Rollnick S. New York, NY: The Guilford Press; 2002:270-283.
• [38]Rollnick S, Mason P, Butler C: Health behavior change: A guide for practitioners. London: Churchill Livingston; 1999.
• [39]Rollnick S, Miller WR: What is motivational interviewing? Behav Cogn Psychother 1995, 23:325-334.
• [40]Yarborough BJH, Yarborough MT, Tehrani K, Funk KL, Stevens VJ, Green CA: Facilitator Guide for the STRIDE Program: A 30-Session Weight Loss and Weight Maintenance Program for People who live with Mental Illness. Portland (OR): Kaiser Permanente Center for Health Research; 2013. Available at: http://www.kpchr.org/stridepublic/ webcite
• [41]Di Noia J, Prochaska JO: Dietary stages of change and decisional balance: a meta-analytic review. Am J Health Behav 2010, 34(5):618-632.
• [42]Borushek A: The Calorie King, Calorie, Fat, & Carbohydrate Counter 2013. Costa Mesa: Family Health Publications; 2012.
• [43]Green CA: STRIDE Study Website. 2013. http://www.kpchr.org/stridepublic/ webcite
• [44]National Health Lung and Blood Institute: Your guide to lowering your blood pressure with DASH, NIH Publication No. 06–4082. National Institutes of Health, U.S. Department of Health and Human Services; 2013. http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf webcite NIH Publication No. 06–4082. 2006
• [45]Expert Panel On Detection: EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama 2001, 285(19):2486-2497.
• [46]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419.
• [47]Ware JE, Sherbourne D: The MOS 36-Item short-form health survey (SF-36): 1. Conceptual framework and item selection. Med Care 1992, 30:473-483.
• [48]Ware JE, Kosinski M: SF-36 physical & mental health summary scales: A manual for users of version 1. Second edition. QualityMetric, Inc: Lincoln, RI; 2001.
• [49]Tunis SL, Croghan TW, Heilman DK, Johnstone BM, Obenchain RL: Reliability, validity, and application of the medical outcomes study 36- item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 1999, 37(7):678-691.
• [50]Eisen SV, Normand SL, Belanger AJ, Spiro A III, Esch D: The revised behavior and symptom identification scale (BASIS-R): reliability and validity. Med Care 2004, 42(12):1230-1241.
• [51]Shern DL, Wilson NZ, Coen AS, Patrick DC, Foster M, Bartsch DA, et al.: Client outcomes II: longitudinal client data from the Colorado treatment outcome study. Milbank Q 1994, 72(1):123-148.
• [52]Conrad KJ, Yagelka JR, Matters MD, Rich AR, Williams V, Buchanan M: Reliability and validity of a modified Colorado symptom index in a national homeless sample. Ment Health Serv Res 2001, 3(3):141-153.
• [53]Becker M: A US experience: consumer responsive quality of life measurement. Can J Commun Ment Health 1998, Winter(3 Suppl):41-58.
• [54]Becker M, Diamond R, Sainfort F: A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. Qual Life Res 1993, 2(4):239-251.
• [55]Diamond R, Becker M: The Wisconsin quality of life index: a multidimensional model for measuring quality of life. J Clin Psychiatry 1999, 60(Suppl 3):29-31.
• [56]Hibbard JH, Stockard J, Mahoney ER, Tusler M: Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 2004, 39(4 Pt 1):1005-1026.
• [57]Awad AG, Voruganti LN: Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scale. Schizophr Res 2004, 70(1):63-67.
• [58]Sallis JF, Grossman RM, Pinski RB, Patterson TL, Nader PR: The development of scales to measure social support for diet and exercise behaviors. Prev Med 1987, 16(6):825-836.
• [59]Sallis JF, Pinski RB, Grossman RM, Patterson TL, Nader PR: The development of self-efficacy scales for healthrelated diet and exercise behaviors. Health Educ Res 1988, 3(3):283-292.
• [60]Foster GD, Wadden TA, Vogt RA, Brewer G: What is a reasonable weight loss? Patients’ expectations and evaluations of obesity treatment outcomes. J Community Psychol 1997, 65(1):79-85.
• [61]Linde JA, Jeffery RW, Finch EA, Ng DM, Rothman AJ: Are unrealistic weight loss goals associated with outcomes for overweight women? Obes Res 2004, 12(3):569-576.
• [62]Thompson FE, Kipnis V, Subar AF, Krebs-Smith SM, Kahle LL, Midthune D, et al.: Evaluation of 2 brief instruments and a food-frequency questionnaire to estimate daily number of servings of fruit and vegetables. Am J Clin Nurt 2000, 71(6):1503-1510.
• [63]Liang KY, Zeger SL: Longitudinal data analysis using generalized linear models. Biometrika 1986, 73(1):13-22.
• [64]Obarzanek E, Sacks FM, Vollmer WM, Bray GA, Miller ER III, Lin PH, et al.: Effects on blood lipids of a blood pressure-lowering diet: the dietary approaches to stop hypertension (DASH) trial. Am J Clin Nurt 2001, 74(1):80-89.
• [65]Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ: Self-reported health status of the general adult U.S. Population as assessed by the EQ-5D and health utilities index. Med Care 2005, 43(11):1078-1086.